July 11, 2016 9:47am

In Hematologic indication, WHY the CRO secrecy, UP +$0.09 – it will dissolve ...

 


 

PSTI has advanced another PI trial - of PLX-R18 cells to treat insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT)

 

The Bottom Line: Is there an issue in naming their “next trial”? PSTI never issues a complete story – WHY, hiding something?

PSTI is UP +$0.09, it will dissipate …